Myriad Pharma cuts 21 jobs, suspends HIV program

Myriad Pharma cuts 21 jobs, suspends HIV programThe company said it would also suspend its HIV maturation program,DCand instead focus on its oncology pipeline.

"After conducting an exhaustive review of our development portfolio and business operations,Shower gelwe have decided to refocus our clinical efforts on oncology, where we believe we can maximize the return on our investments," Chief Executive Adrian Hobden said in a statement.

The company said it would take charges of about $1.2 million related to the job cuts.

As of September 1, 2009, the company had 181 full-time employees.Shower gel

Myriad's most advanced cancer drug candidate is Azixa,DCwhich is currently in its mid-stage trials and is being developed for the treatment of metastatic brain cancer.

Myriad also said it received about $12.7 million from Javelin Pharmaceuticals Inc

In April, Hospira Inc (HSP.N) topped Myriad's bid to buy Javelin.

As of March 31, the company had $148.4 million in cash,DCcash equivalents and marketable securities.

Shares of the company were trading up 3 percent at $3.94 in morning trade Tuesday on Nasdaq.Shower gel